Circulating tumor DNA for surveillance in high-risk melanoma patients: a study protocol
For validation purposes, we conducted a small pilot study using blood samples from 10 patients who had experienced recurrence and had a clinically confirmed BRAF V600E mutation. Detection of BRAF V600E ctDNA using ddPCR varied from 0/5 (0%) in DNA harvested from 4 mL plasma, to 3/5 (60%) in DNA from 8 mL of plasma. These results show promise and highlight the importance of high sensitivity and sampling volumes to ensure accurate detection of low levels of ctDNA.
Authors
- Karin Dreisig
- Estrid Høgdall (ORCID: https://orcid.org/0000-0003-4689-5658)
- Magnús Pétur Bjarnason Obinah (ORCID: https://orcid.org/0000-0002-4817-9834)
- Annette H. Chakera (ORCID: https://orcid.org/0000-0002-3859-0814)
- Christoffer Johansen (ORCID: https://orcid.org/0000-0002-4384-206X)
- Stig E. Bojesen (ORCID: https://orcid.org/0000-0002-4061-4133)
- Lisbet Rosenkrantz Hölmich (ORCID: https://orcid.org/0000-0002-1983-5222)
- Thomas Litman (ORCID: https://orcid.org/0000-0002-6068-901X)
- Tim Svenstrup Poulsen (ORCID: https://orcid.org/0000-0001-9781-0541)
- Sarah A. Al-Halafi
Institutions
- University of Copenhagen (DK)
- Copenhagen University Hospital (DK)
- Gentofte Hospital (DK)
- Rigshospitalet (DK)
Publication Details
- Journal
- Acta Oncologica
- Published
- 2025-02-10
- DOI
- https://doi.org/10.2340/1651-226x.2025.42515
- Citations
- 1
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- Gentofte Hospital
- Dansk Kræftforsknings Fond